440 related articles for article (PubMed ID: 19035119)
1. [Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].
Zhang B; Liu YX; Cao WF; Cao XC; Ning LS; Hao XS
Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):471-6. PubMed ID: 19035119
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
5. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
[TBL] [Abstract][Full Text] [Related]
6. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients.
Puzovic V; Brcic I; Ranogajec I; Jakic-Razumovic J
Neoplasma; 2014; 61(4):439-46. PubMed ID: 24645837
[TBL] [Abstract][Full Text] [Related]
7. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
9. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma.
Mylona E; Nomikos A; Magkou C; Kamberou M; Papassideri I; Keramopoulos A; Nakopoulou L
Histopathology; 2007 Feb; 50(3):338-47. PubMed ID: 17257129
[TBL] [Abstract][Full Text] [Related]
13. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Derived Matrix Metalloproteinase-13 (MMP-13) Expression in Benign and Malignant Breast Lesions.
Ameli F; Ghafourina Nassab F; Masir N; Kahtib F
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2603-2609. PubMed ID: 34452576
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases -2 and -9 in lymph node-negative untreated breast cancer patients.
Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
J BUON; 2013; 18(4):866-73. PubMed ID: 24344010
[TBL] [Abstract][Full Text] [Related]
17. [Expressions of CD147 and matrix metalloproteinase-2 in breast cancer and their correlations to prognosis].
Zhou S; Liu C; Wu SM; Wu RL
Ai Zheng; 2005 Jul; 24(7):874-9. PubMed ID: 16004819
[TBL] [Abstract][Full Text] [Related]
18. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]